{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"76.87","upperLimit":"97.28","value":"90.24"}]}],"title":"1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59.70","upperLimit":"87.64","value":"75.61"}]}],"title":"2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"Progression is an Increase of 25% from lowest value in any of the following (A \"25% increase\" refers to M protein, FLC and bone marrow results and does not refer to bone lesions, soft tissue plasmacytoma or hypercalcemia. The lowest value does not need to be a confirmed value. If the lowest serum Mprotein is ≥ 5 g/dL, an increase in serum M-protein of ≥ 1 g/dL is sufficient to define disease progression.), (In the case where a value is felt to be a spurious result per physician discretion (for example, a possible lab error), that value will not be considered when determining the lowest value.): Serum M-protein (absolute increase must be ≥ 0.5 g/dL) and/or Urine M-protein (absolute increase must be ≥ 200 mg/24 hrs) and/or If the only measurable disease is FLC, the difference between involved and uninvolved FLC levels (absolute increase must be\\>10 mg/dL) and/or If the only measurable disease is BM, bone marrow PC percentage (absolute increase must be ≥ 10%) (Bone marrow criteria for PD","dispersionType":"95% Confidence Interval","groups":[{"description":"CONDITIONING: Patients receive 56 mg/m\\^2 carfilzomib IV over 30 minutes on days -6, -5, -2, and -1. Patients also receive melphalan IV over 1 hour on days -4 and -3. TRANSPLANT: Patients undergo autologous stem cell transplant on day 0. Autologous Bone Marrow Transplantation: Undergo autologous stem cell transplant. Autologous Hematopoietic Stem Cell. Transplantation: Undergo autologous stem cell transplant, Carfilzomib: Given IV. Laboratory Biomarker Analysis: Correlative studies, Melphalan: Given IV","id":"OG000","title":"Dose Level 3"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"At 1 year and 2 years","title":"Progression Free Percentage at 1 and 2 Years Post Registration","type":"SECONDARY","unitOfMeasure":"percentage of patients"}